Print Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Lau K, Chan A. Lau K, & Chan A Lau, Kathleen, and Alex Chan. Vaginal Lactoferrin administration decreases oxidative stress in the amniotic fluid of pregnant women. 2 Minute Medicine, 15 September 2020. McGraw-Hill, 2020. AccessMedicine. https://accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=553167§ionid=249930920APA Citation Lau K, Chan A. Lau K, & Chan A Lau, Kathleen, and Alex Chan. (2020). Vaginal lactoferrin administration decreases oxidative stress in the amniotic fluid of pregnant women. (2020). 2 minute medicine. McGraw-Hill. https://accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=553167§ionid=249930920.MLA Citation Lau K, Chan A. Lau K, & Chan A Lau, Kathleen, and Alex Chan. "Vaginal Lactoferrin administration decreases oxidative stress in the amniotic fluid of pregnant women." 2 Minute Medicine McGraw-Hill, 2020, https://accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=553167§ionid=249930920. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Vaginal Lactoferrin administration decreases oxidative stress in the amniotic fluid of pregnant women by Kathleen Lau, Alex Chan Listen +Originally published by 2 Minute Medicine® (view original article). Reused on AccessMedicine with permission. +1. Administration of vaginal lactoferrin 4 hours before amniocentesis decreased markers of oxidative stress. +Evidence Rating Level: 2 (Good) +While reactive oxygen species (ROS) are a necessary part of metabolism, excessive ROS can result in a condition, Oxidative Stress, which is associated with many negative pregnancy outcomes such as spontaneous abortion, recurrent miscarriage, preterm labour and preterm pre-labour rupture of membranes. Lactoferrin, a naturally found glycoprotein that has antimicrobial properties, has antioxidant properties due its ability to sequester Fe3+ and anti-inflammatory properties. In this open-label, randomized, single centre pilot study, 60 pregnant patients undergoing amniocentesis at 16 weeks were randomized in a 1:1:1 ratio either receive vaginal lactoferrin 300 mg 4 hours before amniocentesis, vaginal lactoferrin 12 hours before amniocentesis or no treatment (control). A portion of the amniotic fluid sample that was collected was used for analysis. Lactoferrin administration 4 hours before the procedure decreased the concentration of thiobarbituric acid reactive substances (TBARS, as a measure of ROS, p<0.0001), decreased oxidative stress index (OSI) (p<0.0001), and increased total antioxidant status (TAS, 35% higher than control p<0.0001, 17% higher than lactoferrin at 12 hours, p<0.001). Lactoferrin administration 12 hours beforehand was associated with decreased concentration of TBARS but to a lower extent (p<0.05). There was no statistically significant difference for OSI or TAS, possibly owing to the short half-life of lactoferrin. Vaginal lactoferrin administration may have potential as adjuvant in dealing with inflammation-related adverse pregnancy outcomes. Future studies with increased sample size, longitudinal design and viable dosing regimens to sustain longer effects are needed to understand the impact of vaginal lactoferrin on pregnancy-related outcomes. +Click to read the study in Frontiers in Medicine +©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.